Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 0.65
(-0.31%)
SEK 0.65
(-0.31%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -7.13 Million SEK | -713500.0% |
| 2022 | -1000.00 SEK | -100100.0% |
| 2021 | 1.00 SEK | -100.0% |
| 2020 | 1.91 Million SEK | 191299900.0% |
| 2019 | 1.00 SEK | 100.0% |
| 2018 | -219 Thousand SEK | 68.35% |
| 2017 | -692 Thousand SEK | 74.06% |
| 2016 | -2.66 Million SEK | 52.94% |
| 2015 | -5.66 Million SEK | 0.0% |
| 2014 | - SEK | -100.0% |
| 2013 | 1.00 SEK | -100.0% |
| 2012 | 26.86 Thousand SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | -7.42 Million SEK | -4.11% |
| 2024 Q3 | - SEK | 100.0% |
| 2024 Q2 | -7.64 Million SEK | -2.93% |
| 2023 Q2 | -5.25 Million SEK | -16.62% |
| 2023 Q4 | -7.13 Million SEK | -9.03% |
| 2023 Q3 | -6.54 Million SEK | -24.55% |
| 2023 FY | -7.13 Million SEK | -713500.0% |
| 2023 Q1 | -4.5 Million SEK | -450500.0% |
| 2022 Q2 | -3.39 Million SEK | 12.99% |
| 2022 FY | -1000.00 SEK | -100100.0% |
| 2022 Q4 | -1000.00 SEK | 99.98% |
| 2022 Q3 | -4.92 Million SEK | -44.83% |
| 2022 Q1 | -3.9 Million SEK | -390400100.0% |
| 2021 Q3 | -6.31 Million SEK | -95.76% |
| 2021 Q1 | -2.85 Million SEK | -173.86% |
| 2021 Q4 | 1.00 SEK | 100.0% |
| 2021 FY | 1.00 SEK | -100.0% |
| 2021 Q2 | -3.22 Million SEK | -12.99% |
| 2020 Q1 | - SEK | 100.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q4 | 3.86 Million SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 FY | 1.91 Million SEK | 191299900.0% |
| 2019 Q4 | -4.98 Million SEK | 0.0% |
| 2019 Q1 | - SEK | 100.0% |
| 2019 FY | 1.00 SEK | 100.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | -219 Thousand SEK | 68.35% |
| 2018 Q4 | -219 Thousand SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | -692 Thousand SEK | 74.06% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | -2.66 Million SEK | 52.94% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | 1.00 SEK | 0.0% |
| 2015 Q4 | - SEK | -100.0% |
| 2015 FY | -5.66 Million SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | -100.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2013 Q4 | 1.00 SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | 1.00 SEK | -100.0% |
| 2012 FY | 26.86 Thousand SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alzinova AB (publ) | -3.27 Million SEK | -117.694% |
| Amniotics AB (publ) | 534 Thousand SEK | 1436.33% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 134.932% |
| Saniona AB (publ) | 1.00 SEK | 713600100.0% |
| Simris Alg AB (publ) | 1.09 Million SEK | 754.079% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 276.896% |
| NextCell Pharma AB | 545.23 Thousand SEK | 1408.789% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | -1496.471% |
| AcouSort AB (publ) | 2.08 Million SEK | 443.077% |
| Active Biotech AB (publ) | -2500.00 SEK | -285340.0% |
| Alligator Bioscience AB (publ) | 2.00 SEK | 356800100.0% |
| Camurus AB (publ) | 100.95 Million SEK | 107.068% |
| Cantargia AB (publ) | - SEK | Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 147.877% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | -480115.343% |
| Mendus AB (publ) | - SEK | Infinity% |
| Kancera AB (publ) | -1950.00 SEK | -365848.718% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | - SEK | Infinity% |
| Lipum AB (publ) | - SEK | Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | -338.868% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 120.256% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | -726.884% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 106.678% |
| Xintela AB (publ) | 398 Thousand SEK | 1892.965% |
| Ziccum AB (publ) | -4.18 Million SEK | -70.351% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 116.299% |
| CombiGene AB (publ) | -1.79 Million SEK | -296.665% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 129.672% |
| Intervacc AB (publ) | 10.48 Million SEK | 168.072% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | -85.014% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 713700.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 178.694% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 326.54% |
| Biovica International AB (publ) | 2.19 Million SEK | 424.511% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 713600100.0% |
| Abliva AB (publ) | - SEK | Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 1119.429% |
| 2cureX AB (publ) | -1000.00 SEK | -713500.0% |
| I-Tech AB | 4.28 Million SEK | 266.729% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 172.876% |
| Cyxone AB (publ) | - SEK | Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | -44.776% |
| Nanologica AB (publ) | 2.97 Million SEK | 340.027% |
| SynAct Pharma AB | - SEK | Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 160.25% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | -2122.049% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 394.268% |
| Pila Pharma AB (publ) | 1.00 SEK | 713600100.0% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 794.163% |